Back

Riociguat in transthyretin cardiac amyloidosis-data from a named patient use program in austria

28 August 2018 (08:30 - 08:39)
Organised by:
Congress Presentation Part of: Cardiovascular drug therapy in special populations Cardiovascular Pharmacotherapy, Other ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Franz Duca

Medical University of Vienna, Vienna (Austria)

7 More presentations in this session

Presentation thumbnail
The monocentric, double-blind, placebo-controlled research of sildenafil impact in pediatric patients with secondary pulmonary hypertension.
Associate Professor I. Palii (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Obesity paradox outcomes after acute myocardial infarction in Japanese is due to optimal medical therapy in overweight patients
Assistant Professor K. Sakamoto (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Elucidating the underlying mechanisms for the differential response to sodium channel blocker antiarrhythmic drugs in obese patients with atrial fibrillation
Assistant Professor M. Mccauley (Chicago, US)
Abstract Slides Video
Presentation thumbnail
The impact of additional mineralocorticoid receptor antagonist on guideline-recommended medical therapy in acute heart failure patients with ischemic heart disease.
Doctor T. Abe (Kawagoe, JP)
Abstract Slides Video
Presentation thumbnail
Polymorphism RS776746 in the gene of CYP3A5 as a possible predictor of clinical efficiency of bisoprolol in patients transplanted with acute coronary syndrome
Doctor V. Shumkov (Saint Petersburg, RU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular drug therapy in special populations

The Event

Event poster

ESC Congress 2018

28 August 2018 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources